<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614794</url>
  </required_header>
  <id_info>
    <org_study_id>ONT-380-206</org_study_id>
    <secondary_id>2015-002801-12</secondary_id>
    <nct_id>NCT02614794</nct_id>
  </id_info>
  <brief_title>A Study of Tucatinib vs. Placebo in Combination With Capecitabine &amp; Trastuzumab in Patients With Advanced HER2+ Breast Cancer</brief_title>
  <acronym>HER2CLIMB</acronym>
  <official_title>Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if tucatinib works better than placebo to help patients who&#xD;
      have a specific type of breast cancer called HER2 positive breast carcinoma. The breast&#xD;
      cancer in this study is either metastatic (spread into other parts of the body) or cannot be&#xD;
      removed completely with surgery. All patients in the study will get capecitabine and&#xD;
      trastuzumab, two drugs that are often used to treat this cancer.&#xD;
&#xD;
      There are two parts to this study. The first part of the study is already complete. Patients&#xD;
      were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since&#xD;
      this part was &quot;blinded,&quot; neither patients nor their doctors knew whether a patient got&#xD;
      tucatinib or placebo.&#xD;
&#xD;
      The second part of the study is called the Unblinded Phase. In this part of the study,&#xD;
      participants and their doctors know which drugs are being given. Participants who used to get&#xD;
      or are currently getting placebo may be able to start taking tucatinib instead.&#xD;
&#xD;
      Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every&#xD;
      day. They will swallow capecitabine pills two times a day during the first two weeks of each&#xD;
      cycle. Patients will get trastuzumab injections from the study site staff on the first day of&#xD;
      every cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, international, multi-center study in patients with progressive&#xD;
      unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment&#xD;
      with trastuzumab, pertuzumab and T-DM1. There are two phases to this trial: the Double-blind&#xD;
      Phase and the Unblinded Phase. In the Double-blind phase, participants were randomized in a&#xD;
      2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab.&#xD;
      In the Unblinded Phase, patients on placebo may be offered tucatinib.&#xD;
&#xD;
      Stratification factors include presence or history of treated or untreated brain metastases&#xD;
      or brain lesions of equivocal significance (yes/no), Eastern Cooperative Oncology Group&#xD;
      (ECOG) Performance Status (0 vs. 1), and region of world (US vs. Canada vs. Rest of World).&#xD;
&#xD;
      Safety assessments will be performed at a minimum of once every three weeks throughout study&#xD;
      treatment and 30 days after the last dose of study drugs. Laboratory assessments will be&#xD;
      performed locally at sites. Left ventricular ejection fraction will be assessed by MUGA or&#xD;
      ECHO at screening and once every 12 weeks thereafter.&#xD;
&#xD;
      For the blinded phase, contrast brain MRI was performed at baseline. Efficacy assessments (CT&#xD;
      of chest, abdomen and pelvis at a minimum) utilized RECIST 1.1 and included patients with&#xD;
      evaluable tumors defined as measurable target lesions and non-measurable non-target lesions.&#xD;
      RECIST assessment was performed at baseline, every 6 weeks for the first 24 weeks, and then&#xD;
      every 9 weeks thereafter. Repeat MRI of the brain was required on this same schedule only in&#xD;
      those patients with brain metastases identified at baseline. All treatment decisions were&#xD;
      made based upon investigator assessment. All patients underwent a repeat MRI of the brain&#xD;
      within 30 days of the end of treatment unless previously performed at time of disease&#xD;
      progression.&#xD;
&#xD;
      For the unblinded phase, RECIST assessments will be performed per standard clinical practice&#xD;
      as determined by investigator with a maximum interval of 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">September 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking applied only during the Double-blind phase of the trial. The Unblinded Phase is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)</measure>
    <time_frame>34.6 months</time_frame>
    <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR</measure>
    <time_frame>34.6 months</time_frame>
    <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>35.9 months</time_frame>
    <description>Defined as time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR</measure>
    <time_frame>34.6 months</time_frame>
    <description>Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR Per RECIST 1.1 as Determined by Investigator Assessment</measure>
    <time_frame>34.6 months</time_frame>
    <description>Defined as achieving a best overall response of confirmed CR or confirmed PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Per RECIST 1.1 as Determined by Investigator Assessment</measure>
    <time_frame>34.6 months</time_frame>
    <description>Defined as the time from the date of randomization to the date of documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR</measure>
    <time_frame>24.6 months</time_frame>
    <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR Per RECIST 1.1 as Determined by Investigator Assessment</measure>
    <time_frame>33.2 months</time_frame>
    <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1</measure>
    <time_frame>34.6 months</time_frame>
    <description>Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR Per RECIST 1.1 as Determined by Investigator Assessment</measure>
    <time_frame>34.6 months</time_frame>
    <description>Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>36.1 months</time_frame>
    <description>As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Dose Modifications</measure>
    <time_frame>35.1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Health Resources Utilization</measure>
    <time_frame>36.1 months</time_frame>
    <description>Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Measure: Ctrough of Tucatinib</measure>
    <time_frame>3.5 months</time_frame>
    <description>Individual plasma tucatinib concentrations at each sampling time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Measure: ONT-993</measure>
    <time_frame>3.5 months</time_frame>
    <description>Individual plasma primary metabolite concentrations at each sampling time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>HER2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tucatinib + capecitabine + trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + capecitabine + trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tucatinib</intervention_name>
    <description>300 mg orally twice daily</description>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>ONT-380, ARRY-380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle</description>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.</description>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>Herceptin, Herceptin Hycleta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral dose twice daily</description>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Double-blind Phase Inclusion Criteria&#xD;
&#xD;
          -  Histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ&#xD;
             hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization&#xD;
             (FISH) methodology&#xD;
&#xD;
          -  Received previous treatment with trastuzumab, pertuzumab, and T-DM1&#xD;
&#xD;
          -  Progression of unresectable locally advanced or metastatic breast cancer after last&#xD;
             systemic therapy (as confirmed by investigator), or be intolerant of last systemic&#xD;
             therapy&#xD;
&#xD;
          -  Have measurable or non-measurable disease assessable by RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate hepatic and renal function and hematologic parameters&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
&#xD;
          -  CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients&#xD;
             must have one of the following:&#xD;
&#xD;
               1. No evidence of brain metastases&#xD;
&#xD;
               2. Untreated brain metastases not needing immediate local therapy&#xD;
&#xD;
               3. Previously treated brain metastases not needing immediate local therapy&#xD;
&#xD;
                    1. Brain metastases previously treated with local therapy may either be stable&#xD;
                       since treatment or may have progressed since prior local CNS therapy&#xD;
&#xD;
                    2. Patients treated with CNS local therapy for newly identified lesions found&#xD;
                       on contrast brain MRI performed during screening for this study may be&#xD;
                       eligible to enroll if the following criteria are met:&#xD;
&#xD;
                  i. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first&#xD;
                  dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days&#xD;
                  prior to first dose of study treatment, or time since surgical resection is ≥ 28&#xD;
                  days.&#xD;
&#xD;
                  ii. Other sites of disease assessable by RECIST 1.1 are present&#xD;
&#xD;
               4. Relevant records of any CNS treatment must be available to allow for&#xD;
                  classification of target and non-target lesions&#xD;
&#xD;
        Double-blind Phase Exclusion Criteria&#xD;
&#xD;
          -  Previously been treated with:&#xD;
&#xD;
               1. lapatinib within 12 months of starting study treatment (except in cases where&#xD;
                  lapatinib was given for ≤ 21 days and was discontinued for reasons other than&#xD;
                  disease progression or toxicity)&#xD;
&#xD;
               2. neratinib, afatinib, or other investigational HER2/epidermal growth factor&#xD;
                  receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously&#xD;
&#xD;
               3. capecitabine (or other fluoropyrimidine) for metastatic disease except in cases&#xD;
                  where capecitabine was given for &lt; 21 days and was discontinued for reasons other&#xD;
                  than disease progression or toxicity. Patients who have received capecitabine for&#xD;
                  adjuvant or neoadjuvant treatment at least 12 months prior to starting study&#xD;
                  treatment are eligible.&#xD;
&#xD;
          -  Clinically significant cardiopulmonary disease&#xD;
&#xD;
          -  Carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Unable for any reason to undergo MRI of the brain&#xD;
&#xD;
          -  Have used a strong CYP3A4 or CYP2C8 inhibitor within 5 half-lives of the inhibitor, or&#xD;
             a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment&#xD;
&#xD;
          -  Have known dihydropyrimidine dehydrogenase deficiency (DPD)&#xD;
&#xD;
          -  CNS Exclusion - Based on screening brain MRI, patients must not have any of the&#xD;
             following:&#xD;
&#xD;
               1. Any untreated brain lesions &gt; 2.0 cm in size, unless approved by medical monitor&#xD;
&#xD;
               2. Ongoing use of systemic corticosteroids for control of symptoms of brain&#xD;
                  metastases at a total daily dose of &gt; 2 mg of dexamethasone (or equivalent)&#xD;
&#xD;
               3. Any brain lesion thought to require immediate local therapy. Patients who undergo&#xD;
                  local treatment for such lesions identified by screening contrast brain MRI may&#xD;
                  still be eligible for the study based on criteria described under CNS inclusion&#xD;
                  criteria&#xD;
&#xD;
               4. Known or suspected leptomeningeal disease (LMD)&#xD;
&#xD;
               5. Poorly controlled seizures Unblinded Phase Crossover Inclusion Criteria -&#xD;
                  Participants who were randomized to the control arm (placebo + trastuzumab +&#xD;
                  capecitabine) must meet the following criteria to be eligible to crossover to the&#xD;
                  experimental arm.&#xD;
&#xD;
          -  Have measurable or non-measurable disease assessable by RECIST 1.1&#xD;
&#xD;
          -  For patients who were randomized to the control arm and on the long-term follow-up&#xD;
             period at the time of crossover screening: have progression of unresectable locally&#xD;
             advanced or metastatic breast cancer after last systemic therapy (as confirmed by&#xD;
             investigator), or be intolerant of last systemic therapy.&#xD;
&#xD;
          -  Have an ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Have a life expectancy of at least 6 months&#xD;
&#xD;
          -  Have adequate hepatic and renal function and hematologic parameters&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
&#xD;
          -  CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients&#xD;
             must have one of the following:&#xD;
&#xD;
             i. No evidence of brain metastases ii. Untreated brain metastases not needing&#xD;
             immediate local therapy iii. Previously treated brain metastases not needing immediate&#xD;
             local therapy&#xD;
&#xD;
          -  Brain metastases previously treated with local therapy may either be stable since&#xD;
             treatment or may have progressed since prior local CNS therapy&#xD;
&#xD;
          -  Patients treated with CNS local therapy for newly identified lesions found on contrast&#xD;
             brain MRI performed during screening for this study may be eligible to enroll if the&#xD;
             following criteria are met:&#xD;
&#xD;
               1. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose&#xD;
                  of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior&#xD;
                  to first dose of study treatment, or time since surgical resection is ≥ 28 days.&#xD;
&#xD;
               2. Other sites of disease assessable by RECIST 1.1 are present Unblinded Phase&#xD;
                  Crossover Exclusion Criteria - Participants who were randomized to the control&#xD;
                  arm (placebo + trastuzumab + capecitabine) will be excluded from the crossover to&#xD;
                  the experimental arm for any of the following reasons.&#xD;
&#xD;
          -  Discontinuation of study treatment due to an adverse event while on the double-blind&#xD;
             phase of the study. If the adverse event leading to discontinuation of study treatment&#xD;
             has resolved, the patient may be allowed to crossover with approval from the medical&#xD;
             monitor.&#xD;
&#xD;
          -  History of exposure to the following cumulative doses of anthracyclines:&#xD;
&#xD;
               -  Doxorubicin &gt; 360 mg/m^2&#xD;
&#xD;
               -  Epirubicin &gt; 720 mg/m^2&#xD;
&#xD;
               -  Mitoxantrone &gt; 120 mg/m^2&#xD;
&#xD;
               -  Idarubicin &gt; 90 mg/m^2&#xD;
&#xD;
               -  Liposomal doxorubicin &gt; 550 mg/m^2&#xD;
&#xD;
          -  History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or&#xD;
             biologically similar to tucatinib&#xD;
&#xD;
             o Exceptions for Grade 1 or 2 infusion related reactions to trastuzumab that were&#xD;
             successfully managed, or known allergy to one of the excipients in the study drugs&#xD;
&#xD;
          -  Have received treatment with any systemic anti-cancer therapy, non-CNS radiation, or&#xD;
             experimental agent within 3 weeks prior to start of crossover therapy&#xD;
&#xD;
          -  Any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1,&#xD;
             with the following exceptions:&#xD;
&#xD;
               -  Alopecia and neuropathy (must have resolved to ≤ Grade 2)&#xD;
&#xD;
               -  CHF (must have been ≤ Grade 1 in severity at the time of occurrence and must have&#xD;
                  resolved completely)&#xD;
&#xD;
               -  Anemia (must have resolved to ≤ Grade 2)&#xD;
&#xD;
          -  Have clinically significant cardiopulmonary disease&#xD;
&#xD;
          -  Have known myocardial infarction or unstable angina within 6 months prior to start of&#xD;
             crossover therapy&#xD;
&#xD;
          -  Require therapy with warfarin or other coumarin derivatives&#xD;
&#xD;
          -  Inability to swallow pills or significant gastrointestinal disease which would&#xD;
             preclude the adequate oral absorption of medications&#xD;
&#xD;
          -  Have used a strong CYP2C8 inhibitor within 5 half-lives of the inhibitor or have used&#xD;
             a strong CYP2C8 or CYP34A inducer within 5 days prior to start of the crossover&#xD;
             (tucatinib) treatment.&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Unable to undergo contract MRI of the brain&#xD;
&#xD;
          -  Have evidence within 2 years prior to start of crossover therapy of another malignancy&#xD;
             that required systemic treatment&#xD;
&#xD;
          -  CNS Exclusion:&#xD;
&#xD;
          -  CNS Exclusion - Based on screening brain MRI, patients must not have any of the&#xD;
             following:&#xD;
&#xD;
               -  Any untreated brain lesions &gt; 2.0 cm in size, unless approved by medical monitor&#xD;
&#xD;
               -  Ongoing use of systemic corticosteroids for control of symptoms of brain&#xD;
                  metastases at a total daily dose of &gt; 2 mg of dexamethasone (or equivalent)&#xD;
&#xD;
               -  Any brain lesion thought to require immediate local therapy. Patients who undergo&#xD;
                  local treatment for such lesions identified by screening contrast brain MRI may&#xD;
                  still be eligible for the study based on criteria described under CNS inclusion&#xD;
                  criteria&#xD;
&#xD;
               -  Known or suspected leptomeningeal disease (LMD)&#xD;
&#xD;
               -  Poorly controlled seizures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Ramos, DO</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinna Palanca-Wessels, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama - Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America - Phoenix</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIO - Central Regulatory Office</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center / David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Physician Network - TRIO</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Marcos Medical Offices</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation TRIO</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center Northern California</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital / University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-0510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center / Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South Region</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital TRIO</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center / Florida</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Health, Inc. TRIO</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East West Palm Beach, FL (SCRI)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists / Advocate Lutheran General Hospital</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University (NYU) Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center / University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Services / Brody School of Medicine East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital / Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania / Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America / Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Healthcare</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina/Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Cancer Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Methodist</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders: Fortworth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Houston Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Regional Medical Center / US Oncology</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Plano East</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology Central Regulatory</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenandoah Oncology P.C.</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Education and Research Precinct</name>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Research Centre</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital</name>
      <address>
        <city>North Sydney</city>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Health Services</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH- Universitat Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH d. Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg, Universitatsklinikum der PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur-Site de Saint Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta / Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement, CHU de Quebec-Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <zip>S4T7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St John's</city>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc (Fnol) - Onkologicka Klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigs Hospiltalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK 2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebaelt - Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Besancon</name>
      <address>
        <city>Besancon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Curie - Centre de Lutte Contre Le Cancer CLCC de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>REIMS Cedex</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Hopital Bretonneau</name>
      <address>
        <city>TOURS Cedex 09</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte - Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf (UKE) - Onkologisches Zentrum - Interdisziplinaere Klinik und Poliklinik fuer Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVO- Institut fUr Versorgungsforschung in der onkologie GbR</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Koln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE- Onkologisches Zentrum Rotkreuzklinikum</name>
      <address>
        <city>Munchen</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach GmbH</name>
      <address>
        <city>Offenbach am Main</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corp.</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49414</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presido Ospedaliero- Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini di Carpi</name>
      <address>
        <city>Carpi</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCSS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. - Ospedali Riuniti di Ancona</name>
      <address>
        <city>Torrette</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cuf Descobertas R. Mario Botas Parque das Nacoes</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto - Hospital Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Leon</name>
      <address>
        <city>Leon</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Univ De Santiago De Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau De Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester Hospital University NHS Foundation Trust</name>
      <address>
        <city>Colchester</city>
        <zip>C04 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital, UK</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <zip>PE3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital- UK</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital (Surrey)</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <results_first_submitted>September 4, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2020</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tucatinib</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>ARRY-380</keyword>
  <keyword>ONT-380</keyword>
  <keyword>HER2 Positive Breast Carcinoma</keyword>
  <keyword>HER2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>HER-2 Positive Breast Cancer</keyword>
  <keyword>HER-2 Positive Breast Carcinoma</keyword>
  <keyword>HER-2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>Recurrent Breast Carcinoma</keyword>
  <keyword>Stage IV Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Metastatic Malignant Neoplasm in the Brain</keyword>
  <keyword>Brain Metastases in Breast Cancer</keyword>
  <keyword>Asymptomatic Brain Metastases in Breast Cancer</keyword>
  <keyword>Low Symptomatic Brain Metastases in Breast Cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02614794/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02614794/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tuc+Cap+Tra</title>
          <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
        </group>
        <group group_id="P2">
          <title>Pbo+Cap+Tra</title>
          <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>On treatment</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>In long term follow up</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat Overall Survival (ITT-OS) Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
      <group_list>
        <group group_id="B1">
          <title>Tuc+Cap+Tra</title>
          <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
        </group>
        <group group_id="B2">
          <title>Pbo+Cap+Tra</title>
          <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="410"/>
            <count group_id="B2" value="202"/>
            <count group_id="B3" value="612"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="496"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="22" upper_limit="80"/>
                    <measurement group_id="B2" value="54" lower_limit="25" upper_limit="82"/>
                    <measurement group_id="B3" value="54" lower_limit="22" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="546"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>0=Normal activity; 1=Symptoms but ambulatory; 2=In bed &lt;50% of the time; 3= In bed &gt;50% of the time; 4=100% bedridden; 5=Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0: Normal activity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1: Symptoms, but ambulatory</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)</title>
        <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
        <time_frame>34.6 months</time_frame>
        <population>Intent-to-treat Progression Free Survival (ITT-PFS) Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their random treatment assignment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)</title>
          <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
          <population>Intent-to-treat Progression Free Survival (ITT-PFS) Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their random treatment assignment).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="4.3" upper_limit="17.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="3.0" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR</title>
        <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT-PFSBrainMets population: included all randomized subjects with brain metastases (evaluated by their random treatment assignment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR</title>
          <description>Defined as the time from the date of randomization to the date of documented disease progression.</description>
          <population>ITT-PFSBrainMets population: included all randomized subjects with brain metastases (evaluated by their random treatment assignment).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.2" upper_limit="11.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="3.0" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Defined as time from randomization to death from any cause</description>
        <time_frame>35.9 months</time_frame>
        <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Defined as time from randomization to death from any cause</description>
          <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="18.3" upper_limit="31.0"/>
                    <measurement group_id="O2" value="17.4" lower_limit="13.6" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR</title>
        <description>Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT - PFS population, subset of participants with measurable disease by BICR at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR</title>
          <description>Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).</description>
          <population>ITT - PFS population, subset of participants with measurable disease by BICR at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="34.8" upper_limit="46.7"/>
                    <measurement group_id="O2" value="23.4" lower_limit="16.6" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR Per RECIST 1.1 as Determined by Investigator Assessment</title>
        <description>Defined as achieving a best overall response of confirmed CR or confirmed PR.</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT - PFS population, subset of participants with measurable disease by investigator at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>ORR Per RECIST 1.1 as Determined by Investigator Assessment</title>
          <description>Defined as achieving a best overall response of confirmed CR or confirmed PR.</description>
          <population>ITT - PFS population, subset of participants with measurable disease by investigator at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="35.6" upper_limit="47.4"/>
                    <measurement group_id="O2" value="23.0" lower_limit="16.3" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS Per RECIST 1.1 as Determined by Investigator Assessment</title>
        <description>Defined as the time from the date of randomization to the date of documented disease progression</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT-PFS Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>PFS Per RECIST 1.1 as Determined by Investigator Assessment</title>
          <description>Defined as the time from the date of randomization to the date of documented disease progression</description>
          <population>ITT-PFS Population: Includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="4.1" upper_limit="13.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.7" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR</title>
        <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
        <time_frame>24.6 months</time_frame>
        <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR</title>
          <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
          <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.3" upper_limit="12.8"/>
                    <measurement group_id="O2" value="6.3" lower_limit="4.2" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DOR Per RECIST 1.1 as Determined by Investigator Assessment</title>
        <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
        <time_frame>33.2 months</time_frame>
        <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>DOR Per RECIST 1.1 as Determined by Investigator Assessment</title>
          <description>Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.</description>
          <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.3" upper_limit="12.9"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.1" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1</title>
        <description>Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1</title>
          <description>Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).</description>
          <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="54.8" upper_limit="64.5"/>
                    <measurement group_id="O2" value="38.1" lower_limit="31.4" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CBR Per RECIST 1.1 as Determined by Investigator Assessment</title>
        <description>Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.</description>
        <time_frame>34.6 months</time_frame>
        <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>CBR Per RECIST 1.1 as Determined by Investigator Assessment</title>
          <description>Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.</description>
          <population>ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" lower_limit="53.1" upper_limit="62.9"/>
                    <measurement group_id="O2" value="37.6" lower_limit="30.9" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AEs)</title>
        <description>As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.</description>
        <time_frame>36.1 months</time_frame>
        <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs)</title>
          <description>As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.</description>
          <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent AE (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 or higher TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-emergent serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Dose Modifications</title>
        <time_frame>35.1 months</time_frame>
        <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Dose Modifications</title>
          <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs resulting in tuc/pbo dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting in tucatinib/placebo dose hold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting in tuc/pbo dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting capecitabine dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting in capecitabine dose hold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting in capecitabine dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting trastuzumab dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs resulting in trastuzumab dose hold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Health Resources Utilization</title>
        <description>Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.</description>
        <time_frame>36.1 months</time_frame>
        <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
          <group group_id="O2">
            <title>Pbo+Cap+Tra</title>
            <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Health Resources Utilization</title>
          <description>Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.</description>
          <population>Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.</population>
          <units>hospitalizations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned hospitalization (other than AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambulatory Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Measure: Ctrough of Tucatinib</title>
        <description>Individual plasma tucatinib concentrations at each sampling time</description>
        <time_frame>3.5 months</time_frame>
        <population>Pharmacokinetics (PK) Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Measure: Ctrough of Tucatinib</title>
          <description>Individual plasma tucatinib concentrations at each sampling time</description>
          <population>Pharmacokinetics (PK) Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.1" spread="260.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.6" spread="210.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1 (Post-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507.1" spread="357.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.2" spread="236.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.6" spread="286.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.8" spread="225.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Measure: ONT-993</title>
        <description>Individual plasma primary metabolite concentrations at each sampling time</description>
        <time_frame>3.5 months</time_frame>
        <population>PK Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Tuc+Cap+Tra</title>
            <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Measure: ONT-993</title>
          <description>Individual plasma primary metabolite concentrations at each sampling time</description>
          <population>PK Analysis Set: Includes all randomized participants who received at least one dose of tucatinib and who had at least one evaluable PK assessment. Participants were evaluated by the treatment actually received.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1 (Post-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1 (Pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36.1 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tuc+Cap+Tra</title>
          <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
        </group>
        <group group_id="E2">
          <title>Pbo+Cap+Tra</title>
          <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Large intestine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Acral lentiginous melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Central nervous system necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="400" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="325" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="256" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Seattle Genetics, Inc.</organization>
      <phone>(855)473-2436</phone>
      <email>medinfo@seagen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

